CN1221256C - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN1221256C
CN1221256C CNB018115527A CN01811552A CN1221256C CN 1221256 C CN1221256 C CN 1221256C CN B018115527 A CNB018115527 A CN B018115527A CN 01811552 A CN01811552 A CN 01811552A CN 1221256 C CN1221256 C CN 1221256C
Authority
CN
China
Prior art keywords
valsartan
tablet
pharmaceutically acceptable
composition
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018115527A
Other languages
English (en)
Chinese (zh)
Other versions
CN1437469A (zh
Inventor
S·M·甘特尔
R·F·瓦格纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1437469A publication Critical patent/CN1437469A/zh
Application granted granted Critical
Publication of CN1221256C publication Critical patent/CN1221256C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB018115527A 2000-06-22 2001-06-20 药物组合物 Expired - Fee Related CN1221256C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22
US09/599,687 2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100510503A Division CN100450478C (zh) 2000-06-22 2001-06-20 药物组合物

Publications (2)

Publication Number Publication Date
CN1437469A CN1437469A (zh) 2003-08-20
CN1221256C true CN1221256C (zh) 2005-10-05

Family

ID=24400655

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018115527A Expired - Fee Related CN1221256C (zh) 2000-06-22 2001-06-20 药物组合物
CNB2005100510503A Expired - Fee Related CN100450478C (zh) 2000-06-22 2001-06-20 药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2005100510503A Expired - Fee Related CN100450478C (zh) 2000-06-22 2001-06-20 药物组合物

Country Status (21)

Country Link
EP (2) EP2072049A3 (enExample)
JP (3) JP2003535895A (enExample)
KR (2) KR100659644B1 (enExample)
CN (2) CN1221256C (enExample)
AU (2) AU8576801A (enExample)
BR (1) BR0111868A (enExample)
CA (1) CA2411882C (enExample)
CZ (1) CZ20024180A3 (enExample)
EC (1) ECSP024389A (enExample)
HK (1) HK1052868A1 (enExample)
HU (1) HUP0301390A3 (enExample)
IL (2) IL153428A0 (enExample)
MX (1) MXPA02012683A (enExample)
NO (1) NO20026123L (enExample)
NZ (2) NZ522953A (enExample)
PL (1) PL358290A1 (enExample)
RU (1) RU2333757C2 (enExample)
SG (1) SG162605A1 (enExample)
SK (1) SK18062002A3 (enExample)
WO (1) WO2001097805A2 (enExample)
ZA (1) ZA200210359B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143233A0 (en) * 1998-12-23 2002-04-21 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
WO2003059345A1 (en) * 2002-01-17 2003-07-24 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
PL2033629T3 (pl) 2004-12-24 2013-04-30 Krka Stała kompozycja farmaceutyczna zawierająca walsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
WO2009048848A1 (en) 2007-10-09 2009-04-16 Novartis Ag Pharmaceutical formulation of valsartan
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
JPH09510225A (ja) * 1994-03-17 1997-10-14 チバ−ガイギー アクチェンゲゼルシャフト バルサルタンを用いる糖尿病性ネフロパシーの治療
BR9609066A (pt) * 1995-06-07 1999-01-26 Searle & Co Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração
MY119312A (en) * 1995-10-06 2005-05-31 Novartis Ag At 1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
ES2189940T3 (es) * 1996-02-29 2003-07-16 Novartis Ag Antagonista de receptor at1 para la estimulacion de la apoptosis.
IL124935A (en) * 1996-05-20 2001-06-14 Janssen Pharmaceutica Nv Dispersible antifungal compositions comprising itraconazole with improved bioavailability
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
IL143233A0 (en) * 1998-12-23 2002-04-21 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
US20040023840A1 (en) * 2000-04-12 2004-02-05 Marc De Gasparo Combination of organic compounds

Also Published As

Publication number Publication date
MXPA02012683A (es) 2003-04-25
JP2003535895A (ja) 2003-12-02
JP2007091758A (ja) 2007-04-12
CA2411882C (en) 2011-09-06
SK18062002A3 (sk) 2003-07-01
SG162605A1 (en) 2010-07-29
HUP0301390A3 (en) 2005-04-28
JP2012211200A (ja) 2012-11-01
EP2072049A2 (en) 2009-06-24
HK1083452A1 (zh) 2006-07-07
CZ20024180A3 (cs) 2003-04-16
KR20050085978A (ko) 2005-08-29
NO20026123L (no) 2003-02-18
AU2001285768B2 (en) 2005-03-10
BR0111868A (pt) 2003-07-01
CN100450478C (zh) 2009-01-14
RU2333757C2 (ru) 2008-09-20
IL153428A0 (en) 2003-07-06
KR20030019450A (ko) 2003-03-06
ZA200210359B (en) 2003-11-13
WO2001097805A2 (en) 2001-12-27
PL358290A1 (en) 2004-08-09
EP2072049A3 (en) 2009-12-30
WO2001097805A3 (en) 2002-08-29
KR100525341B1 (ko) 2005-11-02
NZ540748A (en) 2007-04-27
CN1679551A (zh) 2005-10-12
EP1296677A2 (en) 2003-04-02
IL153428A (en) 2013-12-31
AU8576801A (en) 2002-01-02
NZ522953A (en) 2005-10-28
KR100659644B1 (ko) 2006-12-21
CA2411882A1 (en) 2001-12-27
HUP0301390A2 (hu) 2003-11-28
ECSP024389A (es) 2003-02-06
CN1437469A (zh) 2003-08-20
HK1052868A1 (zh) 2003-10-03
NO20026123D0 (no) 2002-12-19

Similar Documents

Publication Publication Date Title
CN1221256C (zh) 药物组合物
CN1133427C (zh) 瓦尔沙登的固体口服剂量形式
US20100267789A1 (en) Tablet formulations comprising valsartan
CN1705471A (zh) 地非司罗分散片
CN1606438A (zh) 5ht4部分激动剂药物组合物
AU2001285768A1 (en) Solid valsartan pharmaceutical compositions
TWI436760B (zh) 阿利克侖之蓋崙（ｇａｌｅｎｉｃａｌ）調配物
AU2005200815B2 (en) Solid valsartan pharmaceutical compositions
HK1083452B (zh) 药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051005

Termination date: 20140620

EXPY Termination of patent right or utility model